153 related articles for article (PubMed ID: 8258993)
1. Monoclonal antibodies and superantigens: a novel therapeutic approach.
Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando PA; Björklund M
Med Oncol Tumor Pharmacother; 1993; 10(1-2):37-47. PubMed ID: 8258993
[TBL] [Abstract][Full Text] [Related]
2. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells.
Dohlsten M; Sundstedt A; Björklund M; Hedlund G; Kalland T
Int J Cancer; 1993 May; 54(3):482-8. PubMed ID: 8509223
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
5. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219
[TBL] [Abstract][Full Text] [Related]
6. Targeting of superantigens.
Kalland T; Dohlsten M; Abrahmsén L; Hedlund G; Björk P; Lando PA; Sundstedt A; Akerblom E; Lind P
Cell Biophys; 1993; 22(1-3):147-64. PubMed ID: 7889537
[TBL] [Abstract][Full Text] [Related]
7. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
[TBL] [Abstract][Full Text] [Related]
9. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of human colon cancer by antibody-targeted superantigens.
Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685
[TBL] [Abstract][Full Text] [Related]
11. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.
Lando PA; Dohlsten M; Ohlsson L; Kalland T
Int J Cancer; 1995 Aug; 62(4):466-71. PubMed ID: 7635573
[TBL] [Abstract][Full Text] [Related]
12. Immune response during tumor therapy with antibody-superantigen fusion proteins.
Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
14. Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.
Lando PA; Dohlsten M; Hedlund G; Brodin T; Sansom D; Kalland T
Immunology; 1993 Oct; 80(2):236-41. PubMed ID: 7505257
[TBL] [Abstract][Full Text] [Related]
15. T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.
Lando PA; Dohlsten M; Hedlund G; Akerblom E; Kalland T
Cancer Immunol Immunother; 1993; 36(4):223-8. PubMed ID: 8439985
[TBL] [Abstract][Full Text] [Related]
16. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
18. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Hedlund G
Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
[TBL] [Abstract][Full Text] [Related]
19. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; He L; Wang J; Cao X
J Cancer Res Clin Oncol; 2001 Dec; 127(12):718-26. PubMed ID: 11768611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
